Reviewed by the Help Dementia Editorial Team — our editors review every article for accuracy against guidance from the National Institute on Aging, the Alzheimer’s Association, and peer-reviewed sources.
New drugs like lecanemab can slow cognitive and functional decline by approximately 20–30%, but they cannot reverse the damage that Alzheimer’s disease has already caused. This distinction between slowing and reversing is fundamental to understanding what current treatments can and cannot do. A 72-year-old woman diagnosed with early-stage Alzheimer’s who starts lecanemab might experience a slower rate of memory loss and maintain her ability to manage finances or recognize close family members longer than she would without treatment.
However, the drug will not restore memories already lost or repair brain tissue that has been damaged by amyloid plaques. The underlying reason is both biological and practical: Alzheimer’s involves complex, progressive changes to brain structure that become partially irreversible as the disease advances. Current medications target only one aspect of this damage—the accumulation of amyloid-beta protein—but the disease involves multiple interconnected pathologies. No drug has yet been developed that can both stop disease progression and reverse cognitive decline, despite decades of research.
Table of Contents
- Understanding the Difference Between Slowing Disease and Reversing It
- Lecanemab and the Timeline of Effectiveness
- The Role of Amyloid Plaques in a Complex Disease
- What 20–30% Slowdown Actually Means in Daily Life
- Safety Concerns and the Trade-Offs of Amyloid-Targeting Therapies
- Beyond Alzheimer’s: Slowing Decline in Other Progressive Diseases
- The Future: Why Truly Reversing Disease Remains Elusive
- Conclusion
Understanding the Difference Between Slowing Disease and Reversing It
The terminology matters because patients and families often hear about disease-modifying drugs and hope for a cure. Slowing disease means reducing the rate of decline; a person continues to lose cognitive function, but at a slower pace than they would without treatment. Reversing disease would mean restoring lost function—recovering memories, improving cognitive abilities, or bringing someone back to where they were before symptoms began. These are fundamentally different outcomes. Lecanemab works by targeting and removing β-amyloid plaques, which are abnormal protein deposits that accumulate in the brains of people with Alzheimer’s disease.
By clearing these plaques, the drug reduces one of the primary drivers of neurodegeneration. In clinical trials, patients who received lecanemab showed approximately 20–30% slower cognitive decline compared to those who received a placebo over 18 months. This is a meaningful slowing of the disease, but it is not reversal. A person who loses the ability to recognize family members before treatment starts will not regain that ability after taking the medication. The distinction becomes even clearer when you look at what the drug cannot do: it cannot restore brain tissue that has atrophied, repair damaged neurons, or restore synaptic connections that have been lost to disease. The brain does have some capacity for neuroplasticity and compensation, but this is limited, especially in advanced disease.
Lecanemab and the Timeline of Effectiveness
Lecanemab received full FDA approval on July 6, 2023, becoming the first disease-modifying therapy approved for Alzheimer’s disease in the United States. This represented a watershed moment in dementia care because it was the first drug shown to actually slow cognitive decline in people with early-stage disease—not just manage symptoms like memory loss or behavioral changes, but slow the underlying disease process itself. However, approval came with a critical caveat: the drug works best in early stages of disease, before significant brain damage has occurred. The timing window is narrow and crucial.
Studies show that lecanemab is most effective for people in the mild cognitive impairment stage or mild dementia stage of Alzheimer’s disease, when amyloid plaques have begun accumulating but before extensive brain cell death has occurred. Once a person reaches moderate or advanced dementia, the drug’s effectiveness diminishes significantly. This is because irreversible damage has already been done: dead neurons cannot be revived, lost connections cannot be restored, and brain tissue that has shrunk cannot be regenerated. This creates a practical challenge for treatment: the people who would benefit most from a disease-slowing therapy are those diagnosed early, yet early diagnosis remains difficult. Many people are not identified as having cognitive problems until the disease is already fairly advanced, meaning they miss the window when lecanemab could provide maximum benefit.
The Role of Amyloid Plaques in a Complex Disease
While amyloid plaques are a hallmark of Alzheimer’s disease, they are not the only problem happening in the brain. Alzheimer’s involves multiple simultaneous pathologies: amyloid plaques, tangles of a protein called tau, inflammation, loss of connections between neurons (synaptic dysfunction), brain cell death, and vascular changes. Targeting amyloid alone does not address these other processes. Even as plaques are being cleared, tau tangles may continue to accumulate, inflammation may continue, and brain cells may continue to die. This complexity explains why even an effective anti-amyloid drug like lecanemab can only slow decline rather than stop or reverse it.
Imagine trying to slow the deterioration of a building by addressing only one of several major problems—water damage, structural decay, and foundation failure—while leaving the others untouched. The building might deteriorate more slowly, but it will still continue to deteriorate. Similarly, slowing one disease process in Alzheimer’s can extend the time before significant disability occurs, but it cannot fully arrest the disease. Research is ongoing into combination approaches that might target multiple pathologies simultaneously—both amyloid and tau, for instance—but such therapies are still in development. The fundamental principle remains: the further advanced the disease, the more damage is irreversible.
What 20–30% Slowdown Actually Means in Daily Life
When researchers report that a drug slows cognitive decline by 20–30%, this refers to measurable changes on cognitive tests and functional scales. But what does this mean in practical terms for someone living with the disease and their caregivers? The answer is more nuanced than the percentage might suggest, and this is where the debate about clinical significance becomes important. A 20–30% slowdown might mean the difference between losing the ability to manage personal finances in one year versus taking an additional several months to three years to reach that point. It might mean retaining the ability to recognize family members longer, maintaining independence with daily tasks for an extended period, or delaying the need for full-time care. These extensions matter enormously to patients and families—extra months with meaningful functioning can be invaluable.
However, the slowdown does not mean someone maintains their current level of function indefinitely; it means the decline continues, just at a reduced rate. There is legitimate debate among researchers about whether a 20–30% slowing is clinically meaningful or primarily statistically significant. A change that shows up reliably in research studies might not be noticeable to the person living with the disease. Someone whose decline would have been severe might still experience moderate decline while on the medication. Some people taking lecanemab may feel they are maintaining function better, while others may not perceive a meaningful difference in their daily lives.
Safety Concerns and the Trade-Offs of Amyloid-Targeting Therapies
Amyloid-targeting drugs carry serious risks that must be weighed against their benefits of slowing decline. The most significant concern is amyloid-related imaging abnormalities (ARIA), which includes amyloid-related imaging abnormalities in edema (ARIA-E, brain swelling) and microhemorrhages (ARIA-H, small brain bleeds). Some patients taking lecanemab or similar drugs have experienced brain bleeds and strokelike symptoms, including confusion, headache, vision changes, and loss of consciousness. These are not minor side effects; they can be life-threatening or result in permanent disability. For this reason, lecanemab requires regular MRI monitoring to watch for signs of brain swelling or bleeding.
Patients must be carefully screened before starting treatment, and those with certain risk factors—including advanced age, genetic predisposition for Alzheimer’s (carrying the APOE4 gene variant), existing brain microhemorrhages, or cardiovascular disease—may not be good candidates for the medication. Some patients who begin lecanemab must discontinue it after an MRI reveals concerning changes. The decision to start lecanemab, then, is not simply a matter of slowing cognitive decline. It requires weighing the potential benefit of slower disease progression against the real risk of serious side effects. For a person in early-stage disease with no risk factors for bleeding, the benefit might outweigh the risk. For someone with multiple risk factors, discontinuing the drug to prevent a potential stroke or brain hemorrhage might be the safer choice, despite forgoing the potential cognitive benefit.
Beyond Alzheimer’s: Slowing Decline in Other Progressive Diseases
The principle of slowing disease without reversing it applies to many other progressive neurological and medical conditions. In chronic kidney disease, drugs called SGLT2 inhibitors and GLP-1 agonists slow the rate of kidney function decline, protecting kidneys from further damage and delaying the need for dialysis or transplantation. Mounjaro, a newer medication, reduces the risk of kidney function decline and progression to end-stage kidney disease in clinical trials.
Like lecanemab in Alzheimer’s, these drugs do not restore kidney function that has already been lost, but they do extend the period during which a person can maintain reasonable kidney function. The pattern is consistent across many diseases: pharmaceutical science has made impressive progress in slowing disease processes, but reversing established damage remains the frontier. For conditions involving cell death and tissue loss—whether neurons in Alzheimer’s or kidney cells in chronic kidney disease—the irreversibility of damage sets a fundamental limit on what current medications can accomplish.
The Future: Why Truly Reversing Disease Remains Elusive
The gap between slowing disease and reversing it reflects a deeper biological reality: we do not yet know how to regenerate large populations of dead neurons or rebuild lost neural connections. While the brain has some capacity for neuroplasticity—the ability to form new connections and reorganize itself—this capacity is limited, especially as people age.
A neuron that has died will not come back to life; a brain region that has shrunk from cell loss will not spontaneously regenerate. This does not mean that truly disease-reversing therapies will never exist, but it suggests they may require approaches that go beyond pharmaceutical drug development—perhaps regenerative medicine, stem cell therapies, advanced genetic interventions, or technologies we have not yet conceived. In the nearer term, the focus remains on developing drugs that can slow multiple disease processes simultaneously, rather than targeting only amyloid, and on improving our ability to identify and treat people in the earliest stages of disease, before irreversible damage accumulates.
Conclusion
New drugs like lecanemab represent genuine progress in dementia care—they are the first medications proven to slow cognitive decline in Alzheimer’s disease, not merely mask symptoms. A 20–30% slowing of decline can translate to months or years of maintained functioning, which is profoundly important for people living with the disease and their families. However, this progress must be understood within its limits: these drugs slow disease, they do not reverse it, and they carry real risks that must be carefully managed.
The distinction between slowing and reversing disease is not merely semantic; it shapes realistic expectations for treatment. If you or a loved one is facing an Alzheimer’s diagnosis, the question is not whether medication can restore what has been lost, but whether it can extend the time before further loss occurs. For many people in early stages of disease, that extension can be meaningful enough to justify treatment. Discussing these realistic possibilities with a neurologist or dementia specialist can help guide decisions about whether lecanemab or other disease-modifying therapies are right for your individual situation.
